Shares of Cuprina Holdings rocketed 112% on Monday after the Singapore-based biomedical firm announced it had won U.S. regulatory clearance for a biological wound treatment — sterile fly larvae that remove dead tissue from chronic wounds. The stock closed at $8.41, then promptly shed more than 22% in after-hours trading, settling around $6.10 today. For a company worth roughly $6.5 million with only 2.7 million shares outstanding, the violent swings tell a familiar micro-cap story: a real milestone colliding with a fragile balance sheet.
- The FDA Stamp Is Genuine — and Rare.
To the company's knowledge, this is the first maggot debridement product to receive FDA 510(k) clearance using the Lucilia cuprina species.
Cuprina now holds U.S. commercial rights to both maggot species used in wound debridement therapy — a position no competitor currently matches. That matters because chronic non-healing wounds, including diabetic foot ulcers and pressure injuries, affect an estimated 1–2% of the population in developed countries.
The global chronic wound care market was estimated at $13.8 billion in 2024 and is projected to reach $19.5 billion by 2033.
- Revenue Is Nearly Nonexistent.
The company has a market capitalization of just $5.98 million and revenue of only $0.04 million in the last twelve months. FDA clearance opens the door to U.S. sales, but Cuprina must still build a commercial operation — sales teams, hospital relationships, reimbursement coding — from almost nothing. IVF media commercial sales aren't projected until Q4 2026. The gap between regulatory approval and actual cash flow is where many micro-cap biotechs stumble.
- A Reverse Split and Delisting Scare Frame the Rally.
Cuprina completed a 1-for-8 reverse stock split on May 27, 2026, after Nasdaq moved to delist the company for failing the $1.00 minimum bid price.
Over the past 12 months, the stock has lost 91.3%. The FDA news landed just days after the company regained Nasdaq compliance, compressing two positive catalysts into one week — and creating the kind of short-squeeze dynamics common in thinly traded stocks.
- International Expansion Is Promising but Unproven.
Cuprina believes the FDA clearance may support regulatory pathways in Saudi Arabia, Hong Kong, and mainland China.
A laboratory in Saudi Arabia was completed via its associate to manufacture products for the Middle East and North Africa region. But any expansions remain subject to local regulatory requirements and timelines.
The bottom line: Cuprina holds a genuinely unique regulatory asset in a large and growing market. But $40,000 in annual revenue and a stock propped up by a reverse split mean the distance between a cleared product and a viable business remains vast.